					ATTY, DOCKET NO. APPLICATION NO.				
TPE.	à -				9811-013-999 09/830,693				
l	<u>9</u> 87 o	F REFERENCES CITE		ICANI	APPLICANT				
N 2 9 2003	<b>y</b>	(Use several sheets if r	necessary)		Shiau et al.		GROUP		
	OFFICE.				3/30/99 ( § 371 date, 01/2	29/02)	1646_		
& TRADEMA			11.9	S. PATENT DOCU	MENTS		-		$\overline{a}$
		DOCUMENT NUMBER	DATE	J. PAILIN DOOD	NAME	CLASS	TORCLASS	FILING IF APPRO	ME
"EXAMINER INITIAL		OCCUPATION NO.					1		PRIATI
				<del></del>			3	EZ CO	7
						•	1 3	1	
								2	<u>}</u>
							9	2	ندَ 
								兽	_
				EIGN PATENT DO		CLASS	SUBCLASS	TRANSL	ATYON
		DOCUMENT NUMBER	DATE	1	COUNTRY	LEAGS	busecass	YES	NO
0	AA	International Search	10/07/99	PCT					
NK		Report of							
110		PCT/US99/06937	0/04/04	50					
1.0	AB	EP 0 639 584 A1	6/21/94	EP				1	
Ne	AC	WO 92/00091	1/09/92	PCT				1-1	
Ne	AD	WO 93/06121	4/01/93	PCT	<u> </u>		<del></del>	-	
pe	AE	WO 94/28028	12/08/94	PCT			+==		
NR	- AF	WO 97/21993	6/19/97	PCT					
		OTHER RE	FERENCES (/	ncluding Author, Ti	tle, Date, Pertinent Pages, L	Etc.)			
	AG		validated max	ximum likelihood	l enhances crystallogran	phic simulat	ed anneali	ng	
NR	АН				amplified in breast and		cer", Scien	ce (199	<del>)</del> 7)
Ne	Al.	Apriletti et al., "Expres and the use of a ligan Protein Expr. Purif., (1	d-induced co	nformation chan	mone receptor ligand bi ge as a method fo its p	inding doma urification to	in in Esch homogen	eria coli eity",	i
LIC	AJ	Beato et al., "Steroid I	normone rece	eptors: many ac	tors in search of a plot"	, Cell (1995)	83:851-8	<b>57</b> .	
No	- AK	Berry et al., "Role of the context dependent ag 9:2811-2818	ne two activa onistic activit	ting domains of y of the anti-oes	the oestrogen receptor trogen 4-hydroxytamox	in the cell ty ifen", the EN	pe and pro MBO J. (19	omoter 190)	
we	AL	Bourguet et al., "Cryst Nature (1995) 375:37		of the ligand-bind	ding domain fo the hum	an nuclear r	eceptor R	KR-α",	
MC	АМ	Brzozowski et al., "Mo 389:753-758.	olecular basis	of agonism and	l antagonism in the oes	trogen recep	otor", Natu	re (199	7)
ve	AN	Chang et al., "A thyroi PNAS (1997) 94:9040		eceptor coactiva	tor negatively regulated	l by the retin	oblastoma	proteir	۱",
We	AO				a novel histone acetylte P/p300", Cell (1997) 90:		and forms	a	
		Ne	Theo	7 11/1	16/64		CA1	- 323414	l. <b>1</b>

01	PAR	AP	Cohen et al., "Molecular modeling software and methods for medicinal chemistry", J. Med. Chem. (1990) 33:883-894.
N 2	ME	AQ	Collaborative Computational Project, Number 4 "The CCP4 Suite: Programs for Protein Crystallography", Acta Cryst. (1994) D50 760-763.
		AR	Collingwood et al., "A natural transactivation mutation in the thyroid hormone β receptor: Impaced interaction with putative transcriptional mediators", PNAS (1997) 94:248-253.
RAD	Ne	AS	Danielian et al., "Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors", EMBO J. (1992) 11:1025-1033.
	We	АТ	Darimont et al., "Structure and specificity of nuclear receptor-coactivaor interactions", Genes Development (1998) 12:3343-3356.
	W	AU	Desjarlais et al., "Using shape complementarily as an initial screen in designing ligands for a perpention of binding site of known three-dimensional structure", J. Med. Chem. (1988) 31:722-729.
	we	, AV	Ding et al., "Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities", Molecular Endocrinology (19980 12:302-313.
	NR	AW	Douarin et al., "A possible involvement of TIF1 $\alpha$ and TIF1 $\beta$ in the epigenetic control of transcription by nuclear receptors", (1996) 15:6701-6715.
	Ne	AX	Eng et al., "Probing the structure and function of the estrogen receptor ligand binding domain by analysis of mutants with altered transactivation characteristics", Molecular and Cellular Biology (1997) 17:4644-4653.
	Ne	AY	Esnouf et al., "An extensively modified version of MolScript that includes greatly enhanced coloring capabilities", Journal of Molecular Graphics and Modeling (1997), 15:132-134.
	Me	AZ	Farmer et al., "Drug design", Ariens, E.J. ed. (1980) 10:119-143. Academic Press NY.
,	Ne	_ BA	Feng et al., "Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors", Science (1998) 280:1747-1749.
	M	BB	Furey et al., "'Phases' - A program package for the processing and analysis of diffraction data from macromolecules," Am. Crust. Assoc. Mtg. Abstr. (1990) 18:73.
	Ml	ВС	Glass et al., "Nuclear receptor coactivators" Current Opinion in Cell Biology (1997) 9:222-232.
	Ne	BD	Gradishar et al., "Clinical potential of new antiestrogens", (1997) 15:840-852
	we	BE	Grainer et al., "Tamoxifen: Teaching an old drug new tricks?" Nature Medicine (1996) 2:381-385.
,	Ne	BF	Greene et al., "Purification of T47D human progesterone receptor and immunochemical characterization with monoclonal antibodies", Molecular Endocrinology (1988) 2:714-726.
	NR	_BG	Greene et al., "Monoclonal antibodies to human estrogen receptor" PNAS (1980) 77:5115-5119
	Me	ВН	Grese et al., "Molecular determinants of tissue selectivity in estrogen receptor modulators", PNAS (1997) 94:14105-14110.
	Ne	Bi	Hanstein et al., "p300 is a component of an estrogen receptor coactivator complex", PNAS (1996) 93:11540-11545.
	Ne	ВЈ	Heery et al., "A signature motif in transcriptional co-activators mediates binding to nuclear receptors", Nature (1997) 387:733-736.
	Ne	BK	Hegy et al., "Carboxymethylation of the human estrogen receptor ligand binding domain estradiol complex: HPLC/ESMS peptide mapping shows that cysteine 447 does not react with iodoacetic acid", Steroids (1996) 61:367-373.
İ	be	BL	Henttu et al., "AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors", Molecular and Cellular Biology (1997) 17:1832-1839
'			

W	ВМ	Hong et al., "GRIP1, a novel mouse protein that serves as a trasncriptional coactivator in yeast for the hormone binding domains of steroid receptors", PNAS (1996) 93:4948-4952.
Ne	BN	Hong et al., "GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors", Molecular and Cell Biology (1997) 17:2735-2744.
2003	ВО	Horwitz et al., "Nuclear receptor coactivators and corepressors", Molecular Endocrinology (1996) 1167-1177.
LE NO	ВР	Huang et al., "Conic: A fast renderer for space filing molecules with shadows", J. Mol. Graphics, 9:230-242
2	\g	Janknetcht et al., "Rapid and efficient purification of mative histidine-tagged protein expressed by zerombinant vaccinia virus", PNAS (1991) 88:8972-8976.
R	BR	Jordan et al., "Importance of the alkylaminoethoxy side-chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus", Molecular and Cellular Endocrinology (1982) 27:291-306.
De	BS	Jordan, Craig V., "Antiestrogenic action of raloxifene and tamoxifen", Journal of the National Cancel Institute (1998) 90:967-971.
N	вт	Jurutka et al., "Mutations in the 1, 25-dihydroxyvitamin $D_3$ receptor identifying C-terminal amino acids required for transcriptional activation that are functionally dissociated from hormone binding, heterodimeric DNA binding, and interaction with basal transcription factor IIB, in vitro." J. Biol. Chem. (1997) 272:14592-14599.
Nl	υھر	Kakizawa et al., "Ligand-dependent heterodimerization of thyroid hormone receptor and retinoid X receptor", J. Biol. Chem. (1997) 272:23799-23804
Ml	BV	Kalkhoven et al., "Isoforms of steroid receptor co-activator 2 differ in their ability to potentiate transcription by the oestrogen receptor", EMBO J. (1998) 17:232-243.
M	BW	Kamei et al., "A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors", Cell (1996) 85:403-414.
M	ВХ	Kato et al., "Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase", Science (1995) 270:1491-1494.
Me	BY	Kleywegt et al., "Halloweenmasks and bones. In :From first map to final model", Council for the Central Laboratory of the Research Councils (1994) 59-66.
be	_BZ	Korach, Kenneth S., "Insights from the study of animals lacking functional estrogen receptor", Science (1994) 266:1524-1527.
he	CA	Kuiper et al., "Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β", Endocrinology (1997) 138:863-870.
Ne	СВ	Kumar et al., "Functional domains of the human estrogen receptor", Cell (1987) 51:941-951.
Ne	_cc	Kuntz et al., "Structure-based strategies for drug design and discovery", Science (1992) 257:1078-1082.
we	ÇD.	Kussie et al, "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain", Science (1996) 274:948-953.
1	_CE	Landel et al., "The interaction of human estrogen receptor with DNA is modulated by receptor-associated proteins", The Endocrine Seciety (1994) 8-1407-1419.    We We feel CR
M	CF	Landel et al., "Estrogen receptor accessory proteins augment receptor-DNA Interaction and DNA bending", F. Steroid Biochem, Molec. Biol. (1997) 63:59-73.
Ne	CG	Lazennec et al., "Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes", Molecular Endocrinology (1997) 11:1375-1386.
We	∠CH	Lee et al., "Thyroid hormone receptor dimerization function maps to a conserved subregion of the ligand binding domain", Mol. Endocrinol. (1992) 6:1867-1873.
	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	BR BS BT B BN B

	FNL	CI	Li et al., "RAC3 a steroid nuclear receptor associated coactivator that is related to SRC-1 and TIF2", PNAS (1997) 94:8479-8484.
·•"	COUR P.	<del>L</del> CJ	Lin et al., "A conformation switch in nuclear hormone receptors is involved in coupling hormone binding to a corepressor release", Mol. Cell. Biol. (1997) 17:6131-6138.
JAH By	M. Re	CK	Masuyama et al., "Evidence for ligand dependent intramolecular folding of the AF-2 domain in vitamin D receptor activated transcription and coactivator interaction", Mol. Endocrinol. (1997) 11:1507-15
9	We	CL	Meng et al., "Automated docking with grid based energy evaluation", J. Computational Chem. (1992)
	pe	СМ	Merritt et al., "Raster 3D Version 2.0 A Program for Photorealistic Molecular Graphics", Acta Cryst. (1994) D50 869-873.
	pe	CN	Moras et al., "The nuclear receptor ligand binding domain: structure and function", Current Opini Cell Biology (1998) 10:384-391.
	NR	co	Mueller et al., "Complex heterocyclic structures a challenge for computer assisted molecular modeling" Bull. Soc. Chim. Belg. (1988) 97:655-667
	W	СР	Murshudov et al., "Refinement of macromolecular structures by the maximum likelihood method", Acta Cryst (1997) D53 240-255.
	Ne	ca	Navia et al., "Use of structural information in drug design", Curr. Opin. Struct. Biol. (1992) 2:202-210.
	Nl	CR	Nolte et al., "Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ" Nature (1998) 395:137-143.
	NP	cs .	Norman et al., "The rat growth hormone gene contains multiple thyroid response elements", J. Biol. Chem. (1989) 264:12063-12073.
	W	СТ	Norris et al., "Enhancement of estrogen receptor transcriptional activity by the coactivator GRIP-1 highlights the role of activation function 2 in determining estrogen receptor pharmacology", The Journal of Biological Chemistry (1998) 273:6679-6688.
	Me	CU	O'donnell et al., "Thyroid hormone receptor mutations that interfere with transcriptional activation also interfere with receptor interaction with a nuclear protein", Molecular Endocrinology (1991) 5:94-99.
	M	CV	Onate et al., "Sequence and characterization of a coactivator for the steroid hormone receptor superfamily", Science (1995) 270:1354-1357.
	M	CW	Otwinowski et al., "Processing of X-Ray diffraction data collected in oscillation mode", Methods in Enzymology (1997) 276:307-326.
	NR	СХ	Radhakrishnan et al., "Solution structure of the KIX domain of the CBP bound to the transactivation domain of CREB: A model for activator Coactivator interactions", Cell (1997) 91:741-752.
	m	_CY_	Renaud et al., "Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid", Nature (1995) 378:681-689.
-	we	cz	Robertson et al., "Antiestrogen basicity-activity relationships: A comparison of the estrogen receptor binding and antuterotrophic potencies of several analogues of (Z)-1,2-Diphenyl-1-[4[2-(dimethylamino)ethoxy]phenyl]-1-butene (tamoxifen, nolvadex) having altered basicity", J. Med. Chem. (1982) 25:167-171.
	Ne	_DA	Saatcioglu et al., "Mutations in the conserved C-terminal sequence in thyroid hormone receptor dissociate hormone-dependent activation from interference with AP1-activity", Mol. Cell. Biol. (1997) 17:4687-4695.
	Ne	DB	Sadovsky et al., "Transcriptional activators differ in their responses to overexpression of the TATA-Box binding protein", Molecular and Cellular Biology (1995) 15:1554-1563.
	Ne	DC	Seielstad et al., "Analysis of the structural core of the human estrogen receptor ligand binding domain by selective proteolysis/mass spectrometric analysis" Biochemistry (1995) 34:12605-12615.
	100	DD	Seielstad et al., "Molecular characterization by mass spectrometry of the human estrogen receptor ligand- binding domain expressed in Escherichia coli" Molecular Endocrinology, (1995) 9:647-658.

Nathed 11/16/64

~-				
	4	R	DE	Shiau et al., "Activation of the human estrogen receptor by estrogenic and antiestrogenic compounds in Saccharomyces cerevisiae, a positive selection system", Gene (1996) 179:205-210.
0	1		DF	Shiau et al., "The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by Tamoxifen", Cell (1998) 95:927-937.
JAN	7	200	DG	Shibata et al., "Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action Recent Prog. Horm. Res. (1997) 52:141-164.
<b>4</b> 7	R∆N		DH	Smigel et al., "Breast cancer prevention trial shows major benefit, some risk", Journal of the National Cancer Institute (1998) 90:647-648
	d	R	√DI	Smith et al., "Estrogen resistance caused by a mutation in the estrogen receptor gene in a man", he New England Journal of Medicine (1994) 331:1056-1061.
	1	ip	DJ	Spencer et al., "Steroid receptor coactivator-1 is a histone acetyltransferase", Nature (1997) 389:194-198.
	1	re	DK	Tagami et al., "Nuclear receptor corepressors activate rather than suppress basal transcription of genes that are negatively regulated by thyroid hormone", Molecular and Cellular Biology (1997) 17:2642-2648.
	1	re	2 DL	Takeshita et al., "Molecular cloning and properties of a full length putative thyroid hormone receptor coactivator", Endocrinology (1996) 137:3594-3597.
		ve	DM	Tanenbaum et al., "Crystallographic comparison of the estrogen and progesterone receptors ligand binding domains", PNAS (1998) 95:5998-6003.
	Ì	je	DN	Tora et al., "The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties", the EMBO J. (1989) 8:1981-1986.
		pe	_DO	Torchia et al., "The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function", Nature (1997) 387:677-684.
		W	DP	Tsai et al., "Molecular mechanisms of action of steroid/thyroid receptor superfamily members", Annu. Rev. Biochem. (1994) 63:451-86.
	-	be	DQ	Uesugi et al., "Induced α-helix in the VP 16 activation domain upon binding to a human TAF" Science, (1996) 277:1310-1313.
		De	DR	Verlinde et al., "Structure-based drug design: Progress, results and challenges", Structure (1994) 2:577-587.
		Ve	DS	Voegel et al., "The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and independent pathways", the EMBO J (1998) 17:507-519.
	K	Je	DT	Voegel et al., "TIF2 a 160kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors", the EMBO J (1996) 15:3667-3675.
		ue	DU	Wagner et al., "A structural role for hormone in the thyroid hormone receptor", Nature (1995) 378:690-697.
		ve	DV	Wallace et al., "LIGPLOT: a program to generate schematic diagrams of protein ligand interactions", Protein Engineering (1995) 8:127-134.
	L	eQ.	DW	Webb et al., "Tamoxifen activation of the estrogen receptor / AP-1 Pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens", Molecular Endocrinology., (1995) 9:443-456.
·	-	le	DX	White et al., "Ligand independent activation of the oestrogen receptor by mutation of a conserved tyrosine", the EMBO J. (1997) 16:1427-1435.
		be	DY	Whitefield et al., A highly conserved region in the hormone binding domain of the human vitamin D receptor contains residues vital for heterodimerization with retinoid X receptor and for transcriptional activation", Molecular Endocrinology (1995) 9:1166-1179.
	1	re	DZ	Williams et al., "Atomic structure of progesterone complexed with its receptor", Nature (1998) 393:392-396.
	1	ie	EA	Wrenn et al., "Structure-function analysis of the hormone binding domain of the human estrogen receptor by region-specific mutagenesis and phenotypic screening in yeast", The Journal of Biochemistry (1993) 268:24089-24098.
	-			

N Street 11/16/04

PATER	gene", Science (1998) 279:1922-1925.  Zhu et al., "The different hormone-dependent transcriptional activation of thyroid hormone receptor								
120		isoforms is mediated by interplay of their domains", J. Biol. Chem. (1997) 272:9048-9054.							
	PANEMA DE	(X-PLOR Resources) H###xplor.csb.yale.edu/explor-info/ Last accessed on 11/16/98							
	NP EF	Grasp Manual Page http://honiglab.cpmc.columbia.edu/grasp/grasp_man.html Last accessed on 11/16/98							
	EXAMINER	NAND 11/16/04 DATE CONSIDERED							

OIPE	VC)							Sheet 1	of 1
THE JUL 16	5003	BOLLY STORY			ATTY DOCKET NO. 9811-013-999	· · · · · · · · · · · · · · · · · · ·		CATION NO	
¥200	OJENIE E	/ RENCES CITED BY	ADDI ICA	NIT			109/8.	30,693	
LIDAGE	MY C	(Use several sheets if ne		14.1	APPLICANT				
		( Coo co votal offorio in mo	,		Shiau, et al.			<del></del>	
					FILING DATE 3/30/99 (§ 371 date	e, 01/29/0	GROUI (1646)		
	U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING I	
		,							
							REC	EIVE	
							JUL	2 1 200	)3
	•		FOREIGN	PATENT DO	CUMENTS	Ţ	ECH CEN	ITER 160	0/290
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSL	ATION
					ν			YES	NO
		OTHER REFERE							
we	EG	Stephen E. Fawell, et al., Mouse Estrogen Receptor				g and Dim	erization A	ctivities in	the
Ne	EH	David F. V. Lewis, "Mole directed Mutagenesis and	cular Modelli	ng of the Human	Estrogen Receptor and	Ligand Int	eractions B Biol., Vol. 5	ased on Sit 52, No. 1, 1	te- 1995,
( le	EI	Lester F. Harris, et al., "N Domain in Complex with	a Non-Conser	nsus Estrogen Res	sponse Element DNA Se				
110	EJ	Structure & Dynamics, V George J. Maalouf, "Hon				ıman Fetre	gen Recent	or" Iourn	ol of
M		Biomolecular Structure &	Dynamics, V	ol. 15, Number 5	, 1998, 841-851.				
WP	EK	John W. R. Schwabe, et a							NA:
1.0	EL	How Receptors Discrimit John W. R. Schwabe, et a	l., "The oestro	gen receptor reco	gnizes an imperfectly n	alindromic	response e	lement thr	ough
M		an alternative side-chain o	onformation"	Structure, Vol. 3	, 15 February, 1995, 20	1-213.			
110	EM	H. Ewa Witkowska, et al.			_	-	_	ding doma	in by
W. O	EN	Jean-Marie Wurtz, et al.,	"Three-Dimen	sional Models of	Estrogen Receptor Liga	nd Bindin	g Domain C	Complexes,	, , ,
me		Based on Related Crystal 1803-1814.	Structures and	Mutational Struc	ture-Activity Relations	hip Data",	J. Med. Ch	em., 1998,	41,
EXAMINER	٨	Fahed	11/16/	6 DATE	CONSIDERED				
*EXAMINER: considered. Incl	Initial if lude copy	reference considered, whether o	r not citation is in	n conformance with	MPEP 609; Draw line throu	gh citation i	f not in confo	rmance and I	not

(3	AUD I V	" <u>#</u>			
\	E.	(E)		Complete .	If Known
INFO	MAAMY	M DISCLO	SURE	Application Number	09/830,693
	CIT	ATION		Filing Date	January 29, 2002
		-		First Named Inventor	Shiau, Andrew
	PT	O-1449		Art Unit	1631
				Examiner Name	Moran, Majorie A.
Sheet	1	of	1	Attorney Docket Number	061040-0013-US

	•	U.S. PATE	ENT DOCUMENTS				
Examiner Initials	Document Number Number - Kind Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Appro	Date in
	F. D.	FOREIGN PA	TENT DOCUMENTS	<del></del> -			
Examiner Initials	Foreign Patent Document Country Code <sup>2</sup> - Number <sup>3</sup> - Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Class	Subclass	Trans Yes	lation No
NR	WO 97/35195	09-25-1997	The Salk Institute for Biological Studies			:	
Examiner			LITERATURE DOCUMENTS				
Initials	serial, symposium, cata	capital letters), dog, etc.), date, page(s),	title of the article (when appropriate), volume-issue number(s), publisher, ci	title of the i	tem (book, mag untry where pu	azine, jou blished	mal,
Ne	RIBEIRO, R. C. J. et al.	, "Mechanisms of	Thyroid Hormone Action: Recent Progress is Hormon	Insights	from X-ray		
pe		ultiple Receptor l vol. 26, no. 5, 19	Interaction Domains of GRI 98, pages 1191-1197.	P1 Funct	ion in Syne	ergy",	

Examiner	The second secon	- , , , ,	Date	
Diaminici	100	MILL L. IL	Date	J.
Signatura	13-71, 201	11111 160		i i
Signature	14-500	1116161	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if

not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.